Israel could sit out Middle East drug boom

A boom in Middle Eastern pharmaceutical markets is imminent, although Israel may not be a beneficiary of the trend, a report released earlier this month suggested.

April 27, 2006 06:56
1 minute read.
Israel could sit out Middle East drug boom

drugs 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


A boom in Middle Eastern pharmaceutical markets is imminent, although Israel may not be a beneficiary of the trend, a report released earlier this month suggested. Key drivers behind the expected growth surge, according to the study carried out by URCH Publishing, are a combination of liberalizing economic policies and the introduction of mass health insurance. The study suggests that due to the opening up of Middle Eastern markets to European Union and US imports and the implementation of cooperative health insurance in countries such as Saudi Arabia, the next five years could prove very profitable to companies investing in the region. "The Israeli market is more sophisticated than Arab markets, and can be seen as having already passed this 'modernization' stage," said the report's author, Jean-Michel Saliba. A second issue, Saliba noted, is the trade boycott of Israeli products by certain Arab countries. "Although in principle there is nothing stopping Israeli firms selling ... in the Saudi Kingdom, public opinion and the masses are not ready to bury the hatchet yet," Saliba said. Israel, he noted, continues to have a far larger per-capita drug consumption level than its regional neighbors, at $197 in 2002 compared with only $77 in the second placed United Arab Emirates, yet the growth rate in the Israeli pharmaceutical market is around 10 percent compared to 14% in Egypt. Saliba suggested that Petah Tikva-based Teva Pharmaceutical Industries Ltd., the world's largest generic drugmaker, was unlikely to concern itself with trying to penetrate Arab markets, since it "already has strong access and exposure in what is the most lucrative pharma market in the world (the US)." The author also cautioned that "multinationals must be wary of the inadequate level of intellectual property rights protection in the region." It is estimated that US pharmaceutical companies lose around $555 million, in the Middle East alone, due to lack of patent protection.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection